Disease Awareness references

Abedini R, Salehi M, Lajevardi V, Beygi S. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease. Clin Exp Dermatol. 2015;40:722–7.

Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2018; [Epub ahead of print].

Amatya N, Garg AV, Gaffen SL. IL-17 Signaling: The Yin and the Yang. Trends Immunol. 2017;38(5):310– 22.

Arck PC, Slominski A, Theoharides TC, Peters EM, Paus R. Neuroimmunology of stress: skin takes center stage. J Invest Dermatol. 2006;126:1697–704.

Armstrong AW, Harskamp CT, Dhillon JS, Armstrong EJ. Psoriasis and smoking: a systematic review and meta-analysis. Br J Dermatol. 2014;170:304–14.

Aterido A, Julià A, Ferrándiz C, Puig L, Fonseca E, Fernández-López E, et al. Genome-Wide Pathway Analysis Identifies Genetic Pathways Associated with Psoriasis. J Invest Dermatol. 2016;136(3):593–602.

Au SC, Madani A, Alhaddad M, Alkofide M, Gottlieb AB. Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center. J Drugs Dermatol. 2013;12:861–6.

Baliwag J, Barnes DH, Johnston A. Cytokines in psoriasis. Cytokine. 2015;73:342–50.

Becher B, Pantelyushin S. Hiding under the skin: Interleukin-17-producing γδ T cells go under the skin? Nat Med. 2012;18:1748–50.

Becker L, Tom WL, Eshagh K, Benjamin LT, Paller AS. Excess Adiposity Precedes Pediatric Psoriasis. JAMA Dermatol. 2014;150:573–4.

Benson MM, Frishman WH. The Heartbreak of Psoriasis: A Review of Cardiovascular Risk in Patients With Psoriasis. Cardiol Rev. 2015;23:312–6.

Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017b;76:405–17.

Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis. Br J Dermatol. 2015;172:484–93.

Blegvad C, Nybo Andersen AM, Adam A, Zachariae C, Skov L. Psoriasis as a Predictor of Cardiometabolic Comorbidity in Women: A Study Based on the Danish National Birth Cohort. Acta Derm Venerol. 2018. [Epub ahead of print].

Boehncke WH, Boehncke S, Tobin AM, Kirby B. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20:303–7.

Boehncke WH, Boehncke S. More than skin-deep: the many dimensions of psoriatic disease. Swiss Med Wkly. 2014;144:w13968.

Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;pii: S0140-6736(14)61909–7.

Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol. 2018;9:579.

Bonifati C, Berardesca E. Clinical outcome measures of psoriasis. Reumatismo. 2007;59 Suppl 1:64–7.

Brotas AM, Cunha JM, Lago EH, Machado CC, Carneiro SC. Tumor necrosis factor-alpha and the cytokine network in psoriasis. An Bras Dermatol. 2012;87:673–81.

Brunner PM, Koszik F, Reininger B, Kalb ML, Bauer W, Stingl G. Infliximab induces downregulation of the IL-12/IL-23 axis in 6-sulfo-LacNac (slan)+ dendritic cells and macrophages. J Allergy Clin Immunol. 2013 Nov;132(5):1184–1193.

Büchau AS, Gallo RL. Innate immunity and antimicrobial defense systems in psoriasis. Clin Dermatol. 2007;25:616–24.

Buzney CD, Peterman C, Saraiya A, Au SC, Dumont N, Mansfield R, et al. Clearance of psoriasis: the impact of private versus public insurance. J Drugs Dermatol. 2015;14:119–25.

Cai Y, Xue F, Quan C, Qu M, Liu N, Zhang Y, et al. A critical role of the IL-1β-IL-1R signaling pathway in skin inflammation and psoriasis pathogenesis. J Invest Dermatol. 2018; [Epub ahead of print].

Capon F, Burden AD, Trembath RC, Barker JN. Psoriasis and other complex trait dermatoses: from Loci to functional pathways. J Invest Dermatol. 2012;132:915–22.

Capon F, Di Megli P, Szaub J, Prescott NJ, Dunster C, Baumber L, et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet. 20017;122:201–6.

Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, et al. A Large-Scale Genetic Association Study Confirms IL12B and Leads to the Identification of IL23R as Psoriasis-Risk Genes. Am J Hum Genet. 2007;80:273–390.

Chandra A, Ray A, Senapati S, Chatterjee R. Genetic and epigenetic basis of psoriasis pathogenesis. Molec Immunol. 2015;64;313–23.

Chandrakuma SF, Yeung J. Interleukin-17 antagonists in the treatment of psoriasis. J Curaneous Med Surg. 2014;18:223–8.

Chandran V. The genetics of psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;44:149–56.

Chiesa Fuxench ZC, Callis Duffin K, Siegel M, Van Voorhees AS, Gelfand JM. Validity of the Simple-Measure for Assessing Psoriasis Activity (S-MAPA) for objectively evaluating disease severity in patients with plaque psoriasis. J Am Acad Dermatol. 2015;73:868–70.

Chiricozzi A, Romanelli P, Volpe E, Borsellino G, Romanelli M. Scanning the Immunopathogenesis of Psoriasis. Int J Mol Sci. 2018;19(1). pii: E179.

Chiticozzi A, Krueger JC. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs. 2013;22:993–1005.

Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol. 2008;8:458–66.

Christophers E. Psoriasis--epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26:314–20.

Claudepierre P, Lahfa M. Levy P, Barnetche T, Bonnet I, Aubert R, et al. The impact of psoriasis on professional life: PsoPRO, a French national survey. J Eur Acad Dermatol Venereol. 2018;32:1702–9.

ClinicalTrials.gov. Clinical Assessment and Psychosocial Impact of Psoriasis (EPIDEPSO). NCT01964443 [cited 5 Dec 2015] Available at https://clinicaltrials.gov/ct2/show/NCT01964443. Accessed December 2015.

Cohen BE, Martires KJ, Ho RS. Psoriasis and the Risk of Depression in the US Population: National Health and Nutrition Examination Survey 2009-2012. JAMA Dermatol. 2016;152(1):73–9.

Cohen SN, Baron SE, Archer CB. Guidance on the diagnosis and clinical management of psoriasis. Clin Experiment Dermatol. 2012;37(Suppl 1):13–8.

Coto E, Santos-Juanes J, Coto-Segura P, Alvarez V. New psoriasis susceptibility genes: momentum for skin-barrier disruption. J Invest Dermatol. 2011;131(5):1003–5.

Dalgard FJ, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GB, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135:984–91.

Di Meglio P, Nestle FO. The role of IL-23 in the immunopathogenesis of psoriasis. F1000 Biol Rep. 2010;2. pii:40.

Diani M, Altomare G, Reali E. T-cell responses in psoriasis and psoriatic arthritis. Autoimmunity reviews. 2015;14:286-92.

Duffin KC, Papp KA, Bagel J, Levi E, Chen R, Gottlieb AB. Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2. J Drugs Dermatol. 2017;16:147–153.

Edson-Heredia E, Zhu B, Guo J, Maeda-Chubachi T, Lebwohl M. Disease burden and quality of life in psoriasis patients with and without comorbid psoriatic arthritis: results from National Psoriasis Foundation panel surveys. Cutis. 2015;95:173–8.

Edson-Heredia E, Zhu B, Lefevre C, Wang M, Barrett A, Bushe CJ, et al. Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink. J Eur Acad Dermatol Venereol. 2015;29:955–63.

Elias PM, Wood LC, Feingold KR. Epidermal pathogenesis of inflammatory dermatoses. Am J Contact Dermat. 1999;10:119–26.

Evers AW, Verhoeven EW, Kraaimaat FW, de Jong EM, de Brouwer SJ, Schalkwijk J, et al. How stress gets under the skin: cortisol and stress reactivity in psoriasis. Br J Dermatol. 2010;163:986–91.

Feldman SR, Bushnell DM, Klekotka PA, Scanlon M, Martin ML, Wade SW, et al. Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice. J Dermatolog Treat. 2016;27(3):224–7.

Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64 Suppl 2:ii65-8; discussion ii69–73.

Fu Y, Lee CH, Chi CC. Association of Psoriasis With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. JAMA Dermatol. 2018;154:1417–23.

Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52:65–70.

Garg A, Chren MM, Sands LP, Matsui MS, Marenus KD, Feingold KR, et al. Psychological stress perturbs epidermal permeability barrier homeostasis: implications for the pathogenesis of stress-associated skin disorders. Arch Dermatol. 2001;137:53–9.

Goldenstein-Schainberg C, Favarato M, Ranza R. Current and relevant concepts in psoriatic arthritis. Rev Bras Reumatol 2012;52:98–106.

Gómez-García F, Ruano J, Gay-Mimbrera J, Aguilar-Luque M, Sanz-Cabanillas JL, Hernández Romero JL, et al. A scoping review protocol to explore the use of interleukin-1-targeting drugs for the treatment of dermatological diseases: indications, mechanism of action, efficacy, and safety. Dermatol Ther (Heidelb). 2018;8(2):195–202.

Gonzalez J, Cunningham K, Perlmutter J, Gottlieb A. Systematic Review of Health-Related Quality of Life in Adolescents with Psoriasis. Dermatology. 2016;232(5):541—549.

Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, et al. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. N Engl J Med. 2015;373:136–44.

Gottlieb A, Sullivan J, van Dorn M, Kubanov A, You, R, Hugot S, et al. Secukinumab efficacy and safety in subjects with moderate to severe palmoplantar psoriasis in a Phase 3b study (GESTURE). 23rd World Congress of Dermatology. Vancouver, Canada. June 8–13, 2015. Abstract 2984723.

Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263-71.

Griffiths CEM, Jo SJ, Naldi L, Romiti R, Guevara-Sangines E, Howe T, et al. A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey. Br J Dermatol. 2018; [Epub ahead of print].

Handa S. Newer trends in the management of psoriasis at difficult to treat locations: scalp, palmoplantar disease and nails. Indian J Dermatol Venereol Leprol. 2010;76(6):634–44.

Hao JQ. Targeting interleukin-22 in psoriasis. Inflammation. 2014;37(1):94–9.

Harvima IT, Nilsson G, Suttle MM, Naukkarinen A. Is there a role for mast cells in psoriasis? Arch Dermatol Res. 2008;300:461–78.

Heller MM, Lee ES, Koo JY. Stress as an influencing factor in psoriasis. Skin Therapy Lett. 2011;16:1–4.

Hunjan MK, Maradit Kremers H, Lohse C, Tollefson M. Association between obesity and pediatric psoriasis. Pediatr Dermatol. 2018;35:e304–5.

Jensen P, Zachariae C, Skov L, Zachariae R. Sleep disturbance in psoriasis: a case-controlled study. Br J Dermatol. 2018;179:1376–84.

Kaaz K, Szepietowki JC, Matusiak L. Influence of Itch and Pain on Sleep Quality in Atopic Dermatitis and Psoriasis. Acta Derm Venereol. 2018. [Epub ahead of print].

Korman NJ, Zhao Y, Pike J, Roberts J. Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA. Clin Exp Dermatol. 2016;41(5):514–21.

Lande R, Botti E, Jandus C, Dojcinovic D, Fanelli G, Conrad C, et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 2014;5:5621.

Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449:564–9.

Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. New Engl J Med. 2014;371:326–38.

Langley RG, Lebwohl M, Krueger GG, Szapary PO, Wasfi Y, Chan D, et al. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate to severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol. 2015; 172:1371–83.

Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015;373:1318–28.

Lee JY, Kang S, Park JS, Jo SJ. Prevalence of psoriasis in Korea: a population-based epidemiological study using the Korean national health insurance database. Ann Dermatol. 2017; 29(6):761–7.

Leonardi C, Blauvelt A, Langley G, Luger T, Ohtsuki M, Cameron S, et al. Maintenance of efficacy results from UNCOVER-1: A Phase 3 trial of ixezimumab for moderate-to-severe plaque psoriasis. 23rd World Congress of Dermatology. Vancouver, Canada. June 8–13, 2015. Abstract 2983466.

Lønnberg AS, Zachariae C, Skov L. Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Investig Dermatol. 2014 Sep 15;7:251–9.

Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227–55.

Lubrano E, Cantini F, Costanzo A, Girolomoni G, Prignano F, Olivieri I, et al.  Measuring psoriatic disease in clinical practice. An expert opinion position paper. Autoimmun Rev. 2015;14:864–74.

Maddur MS, Miossec P, Kaveri SV, Bayry J. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol. 2012;181:8–18.

Mahil SK, Capon F, Barker JN. Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol. 2016;38:11–27.  PubMed PMID: 26573299.

Manalo IF, Gilbert KE, Wu JJ. Time to Raise the Bar to Psoriasis Area Severity Index 90 and 100. J Drugs Dermatol. 2015;14:1086–8.

Manolache L, Petrescu-Seceleanu D, Benea V. Life events involvement in psoriasis onset/recurrence. Int J Dermatol. 2010;49:636–41.

Marshall, C. Clinical review: Psoriasis. Gponline June 2015 [cited January 2016]. Available from: http://www.gponline.com/clinical-review-psoriasis/dermatology/psoriasis/article/1352822.

Mendes VS, Cota LOM, Costa AA, Oliveira AMSD, Costa FO. Periodontitis as another comorbidity associated with psoriasis: A case-control study. J Periodontol. 2018. [Epub ahead of print].

Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1–10.

Mrowietz U, Leonardi CL, Girolomoni G, Toth D, Morita A, Balki SA, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73:27–36.

National Psoriasis Foundation. 2018 [cited 25 July 2018] Available from: https://www.psoriasis.org/about-psoriasis#diagnosed.

National Psoriasis Foundation. 2018. [cited 25 July 2018] Available from: https://www.psoriasis.org/about-psoriasis.

Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496–509.

Ngan V, Oakley A. Nail Psoriasis. DermnetNZ, February 2016. [accessed 25th July 2018] available from: http://dermnetnz.org/scaly/nail-psoriasis.html

Palfreeman AC, McNamee KE, McCann FE. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Des Devel Ther. 2013;7:201–10.

Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016b;175:273–86.

Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–85.

Parisi R, Webb RT, Kleyn CE, Carr MJ, Kapur N, Griffiths CEM, et al. Psychiatric morbidity and suicidal behaviour in psoriasis: a primary care cohort study. Br J Dermatol. 2018; [Epub ahead of print].

Pasch MC. Nail Psoriasis: A Review of Treatment Options. Drugs. 2016; 76:675-705. Published online 4th April 2016.

Paul C, Girolomoni G, Radtke MA, Sampogna F, Spuls P, Kirby B, et al. Impact of Alexithymia and Disease Characteristics on Work Productivity and Activity In Psoriasis Patients With Short Disease Duration: Epidepso Multicentre Study. Value Health. 2015;18:A425–6.

Paul C, Lacour J-P, Tedremets L, Kreutzer K, Jazayeri S, Adams S, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29:1082–90.

Pezzolo E, Naldi L. The relationship between smoking, psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018. [Epub ahead of print].

Rahman P, Elder JT. Genetics of psoriasis and psoriatic arthritis: a report from the GRAPPA 2010 annual meeting. J Rheumatol. 2012;39:431–3.

Reich K, Griffiths C, Lebwohl M, Nikai E, Edson-Heredia E, Lin CY, et al. Complete resolution of psoriasis is associated with greater improvements in itch and health-related quality of life: an anlalysis from UNCOVER-1, a phase 3 clinical trial of ixikizumab. EADV. Copenhagen, Denmark. 7–11 October, 2015. P1642.

Reich K, Papp K, Blauvelt A, Tyring SK, Sinclair R, Thaci D, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised, controlled, phase 3 trials. Lancet. 2017c; Jul 15;390(10091):276-288. doi: 10.1016/S0140-6736(17)31279-5.

Reich K, Papp KA, Matheson RT, Tu JH, Bissonnette R, Bourcier M, et al. Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis. Exp Dermatol. 2015b;24:529–35.

Richard MA, Corgibet F, Beylot-Barry M, Barbaud A, Bodemer C, Chaussade V, et al. Sex- and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the OBJECTIFS PEAU study. J Eur Acad Dermatol Venereol. 2018; [Epub ahead of print].

Riveira-Munoz E, He SM, Escaramís G, Stuart PE, Hüffmeier U, Lee C, et al. Meta-analysis confirms the LCE3C_LCE3B deletion as a risk factor for psoriasis in several ethnic groups and finds interaction with HLA-Cw6. J Invest Dermatol. 2011;131:1105–9.

Roman M, Chiu MW. Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy. Drug Des Devel Ther. 2017;11:2065–75.

Rousset L, Halioua B. Stress and psoriasis. Int J Dermatol. 2018;57:1165–72.

Sabat R, Philipp S, Höflich C, Kreutzer S, Wallace E, Asadullah K, et al. Immunopathogenesis of psoriasis. Exp Dermatol. 2007;16(10):779–98.

Schaefer CP, Cappelleri JC, Cheng R, Cole JC, Guenthner S, Fowler J, et al. Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States. J Am Acad Dermatol. 2015;73:585–593.

Sewerin P, Brinks R, Schneider M, Haase I, Vordenbӓumen S. Prevalence and incidence of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2018. [Epub ahead of print].

Shah K, Paris M, Mellars L, Changolkar A, Mease PJ. Real-world burden of comorbidities in US patients with psoriatic arthritis. RMD Open. 2017;3(2):e000588.

Shalom G, Zisman D, Babaev M, Horev A, Tiosano S, Schonmann Y, et al. Psoriasis in Israel: demographic, epidemiology, and healthcare services utilization. Int J Dermatol. 2018; [Epub ahead of print].

Singh S, Pradhan D, Puri P, Ramesh V, Aggarwal S, Nayek A, et al. Genomic alterations driving psoriasis pathogenesis. Gene. 2019. [Epub ahead of print].

Skroza N, Proietti I, Pampena R, La Viola G, Bernardini N, Nicolucci F, et al. Correlations between psoriasis and inflammatory bowel diseases. Biomed Res Int. 2013:983902.

Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol. 2014;133:1032–40.

Soler DC, McCormick TS. The dark side of regulatory T-cells in psoriasis. J Invest Dermatol. 2011;131:1785–6.

Sorensen EP, Fanucci KA, Saraiya A, Volf E, Au SC, Argobi Y, et al. Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased Ustekinumab Efficacy in Psoriasis Patients. J Drugs Dermatol. 2015;14:893–8.

Steffen S, Abraham S, Herbig M, Schmidt F, Blau K, Meisterfeld S, et al. Toll-like receptor-mediated upregulation of CXCL16 in psoriasis orchestrates neutrophil activation. J Invest Dermatol. 2018;138(2):344–54.

Stuart PE, Nair RP, Tsoi LC, Tejasvi T, Das S, Kang HM, et al. Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture. Am J Hum Genet. 2015;97:816–36.

Sugiyama H, Gyulai R, Toichi E, Garaczi E, Shimada S, Stevens SR, et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol. 2005;174(1):164–73.

Svedbom A, Dalén J, Mamolo C, Cappelleri JC, Mallbris L, Petersson IF, et al. Increased Cause-specific Mortality in Patients with Mild and Severe Psoriasis: A Population-based Swedish Register Study. Acta Derm Venereol. 2015 5;95:809–15.

Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomised controlled trial.  J Am Acad Dermatol 2015;73:400–9.

Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol. 2004;146:1–12.

Torii H, Sato N, Yoshinari T, Nakagawa H; Japanese Infliximab Study Investigators. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab. J Dermatol. 2012;39:253–9.

Twelves S, Mostafa A, Dand N, Burri E, Farkas K, Wilson R, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2018; [Epub ahead of print].

Valent F, Tullio A, Errichetti E, Stinco G. The epidemiology of psoriasis in an Italian area: population-based analysis of administrative data. G Ital Dermatol Venereol. 2018; [Epub ahead of print].

Walsh JA, Jones H, Mallbris L, Duffin KC, Krueger GG, Clegg DO, et al. The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA. Psoriasis (Auckl). 2008;8:65–74.

Williamson L, Dalbeth N, Dockerty JL, Gee BC, Weatherall R, Wordsworth BP. Extended report: nail disease in psoriatic arthritis–clinically important, potentially treatable and often overlooked. Rheumatology March 2004;43(6):790–794.

Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Dermatol 2003;4:441–7.



In this Knowledge Centre we provide an overview of psoriasis including epidemiology, diagnosis and treatment.



Read about the established topical, systemic and biologic treatments available for psoriasis as well as novel treatments including tumour necrosis factor-α (TNFα) and interleukin (IL) antagonists.